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DepositionAlterations in regional lung function due to respiratory infection have a signiﬁcant effect on the deposition of
inhaled treatments. This has consequences for treatment effectiveness and hence recovery of lung function. In
order to advance our understanding of respiratory infection and inhaled treatment delivery, we must develop
imaging techniques that can provide regional functional measurements of the lung.
In this review, we explore the role of functional imaging for the assessment of respiratory infection and
development of inhaled treatments. We describe established and emerging functional lung imaging methods.
The effect of infection on lung function is described, and the link between regional disease, function, and inhaled
treatments is discussed. The potential for lung function imaging to provide unique insights into the functional
consequences of infection, and its treatment, is also discussed.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Respiratory infection has a profound effect on lung function. Subse-
quently, altered lung function has a signiﬁcant impact on the delivery of
inhaled treatments. Our ability to understand and treat respiratory
infection would be greatly enhanced by the ability to consider the
regional functional consequences of respiratory infection, and how thisthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Basic anatomical elements of the lungs. During inspiration, the diaphragm contracts
and ﬂattens, enlarging the thoracic cavity resulting in a decrease in pressure in the pleural
cavity. This in turn expands the lungs, reducing pressure in the alveoli causing gas to be
drawn in through the trachea and conducting airways.
101S. Dubsky, A. Fouras / Advanced Drug Delivery Reviews 85 (2015) 100–109may affect inhaled treatment delivery. Lung function has traditionally
been assessed using spirometry; by measuring the ﬂow of gas at the
mouth, the function of the lungs as a whole is calculated. However, the
effects of disease on lung function are predominantly restricted to local
regions within the lung, providing motivation for the development of
imaging methods capable of providing regional lung function measure-
ments. Functional lung imaging has the potential to address unanswered
questions of lung pathophysiology [1], and to provide new insight into
the development of inhaled treatments of lung disease [2].
In this review we establish the beneﬁt of functional lung imaging in
the assessment and treatment of respiratory infection. Themain focus is
to describe established and emerging functional lung imagingmethods,
with speciﬁc focus on those that may be used in lung functionmeasure-
ment in respiratory tract infection and for development and assessment
of inhaled treatments. Table 1 summarizes the different techniques
discussed, including advantages and limitations of each. The effect of
infection on lung function is described, and the link between regional
disease, function, and inhaled treatments is discussed. The potential
for lung function imaging to provide unique insights into the functional
consequences of infection, and its treatment, is also discussed.1.1. Lung function in infection and disease
Breathing is a mechanical process where the respiratory muscles
work together to produce driving pressures to expand and draw air
into the lung for gas exchange [3]. The ﬂow of air inside the lungs, and
hence the regional ventilation and function, is determined bymechani-
cal properties, most notably the resistance and compliance. The driving
pressure across the respiratory system needs to overcome the total
pulmonary resistance against the ﬂow, the static elastic recoil of the
alveolar tissue and the thoracic cage against the increasing volume,
and also the inertial force of the gas motion.
Fig. 1 shows the basic anatomical elements of the lungs. During in-
spiration, the dome-shaped diaphragm contracts and ﬂattens, enlarging
the thoracic cavity resulting in a decrease of both the pleural pressure
and the alveolar pressure inside the lung. This establishes a positive
pressure gradient along the airway tree causing airﬂow into the lung.
During expiration, the diaphragm relaxes, and gas is expelled from the
lung due to elastic recoil of the lung tissue and chest wall.Table 1
Established and emerging lung imaging methods.
Section Modality Advantages
Established methods
2.1 Computed tomography High spatial res
2.2 4DCT registration-based ventilation Regional functio
High spatial res
2.3 Hyperpolarized MRI Regional functio
Zero radiation d
2.4 Electrical impedance tomography Bedside imaging
High temporal r
Regional functio
Zero radiation d
2.5 Nuclear Imaging methods Regional functio
Deposition mea
Emerging functional imaging
3.2 Grating interferometry Very sensitive t
3.3 Propagation-based phase contrast imaging Simple to imple
Dynamic imagin
High contrast w
3.4 Functional lung imaging using phase contrast Regional functio
Dynamic inform
3.5 Laboratory PBI Improved accesThe lung contains structures that cover a range of scales in order to
deliver air to a large surface area for gas exchange [4]. The airways ex-
hibit a branching geometry in which elements are interdependent [5].
Emergent behavior and internal feedback mechanisms mean that
while local effects must be resolved, the entire respiratory system
must be interrogated as a whole, and the response of isolated tissue
may not easily predict whole organ response, for example when
airways are constricted in asthma [6–10]. Imaging is well placed to
deliver this detailed, yet holistic view of lung function in situ.
Disease and infection alter the mechanical properties within the
lung, leading to regional alterations in lung function. For example,
pulmonary ﬁbrosis will alter the compliance of the lung parenchyma,
leading to regional alterations in tissue expansion, even in the very
early stages of the disease [11]. Asthma results from airway hyper-
responsiveness. Exacerbations occur whereby the airways constrict
and narrow, causing an increase in airway resistance that can lead to
difﬁculty breathing and regional ventilation defects [5,6,8,12–14].
Inﬂammation associated with chronic obstructive pulmonary disease
(COPD) leads to the destruction of elastin, which reduces lung elasticity.
This results in less elastic recoil (increased compliance) reducing the
ability to empty the lungs, and decreasing peak expiratory ﬂow [15].Limitations
olution High radiation dose
Limited functional information
No dynamic information
nal measurement
olution
Very high radiation dose
nal measurement
ose
High cost
Lower resolution
Limited availability
esolution
nal measurement
ose
Very low resolution
nal measurement
surement
Poor temporal resolution
High cost
Logistically challenging contrast agent required
o changes in lung structure Very poor temporal resolution
Challenging imaging setup
ment
g
ithin lung tissue
Less sensitive to phase contrast
Requires highly coherent X-rays
nal measurement
ation
Currently requires highly coherent X-rays
s for researchers Under development
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changes in the lung that lead to altered lung function. Infection with
Legionella pneumophila bacteria has been shown to cause alveolar wall
thickening, edema, focal pneumonia, and lung injury over the course
of infection in mice [16]. Patients with cystic ﬁbrosis are particularly
susceptible to Pseudonomas aeruginosa infection. The resulting inﬂam-
matory response proceeds to cause increased secretions, bronchial
constriction, pneumonia and damage to the lung parenchyma [17–19].
As a result, typical spirometric lung function metrics, including peak
expiratory ﬂow and tidal volume, are reduced over the course of the
infection [20,21]. Pulmonary infection with Listeria monocytogenes sim-
ilarly shows inﬂammatory responses in mice [22]. Bacterial infection, in
particular Haemophilus inﬂuenzae, has been linked to exacerbations in
patients with COPD [23,24]. This leads to inﬂammatory changes and
signiﬁcantly reduced lung function.
It is clear that inﬂammatory responses and structural changes
resulting from pulmonary infection lead to an overall reduction in
lung function. Many of these effects are regional and global measure-
ments such a spirometry will fail to show the details of these effects.
Pulmonary infection is typically treated using inhaled antibiotics.
The effectiveness of this treatment is dependent on local concentrations
of the inhaled agents, which will be dramatically affected by local lung
function and airﬂow [2,25]. This link between regional lung function
and effectiveness of inhaled treatment is explored in the following
section.
1.2. Assessment of inhaled treatments using functional lung imaging
Airﬂow is not uniform throughout the lung, and the regional nature
of most lung disease can increase this heterogeneity. When some re-
gions of the lung are diseased and underperforming, healthy regions
may compensate, masking the disease from global functional measures
such as spirometry [11,26]. Assessment of treatment outcomes using
global lung function measures will be similarly hindered, a major
challenge for development of novel drugs and delivery mechanisms.
The effectiveness of inhaled treatments for lung diseases is signiﬁ-
cantly affected by the deposition distribution within the lung. This is
determined by two categories of factors: particle related factors, such
as shape, size, density and concentration of the inhalant, and patient re-
lated factors that relate directly to airﬂow [25]. These patient-related
factors include airway obstructions, which cause local ﬂow changes
that increase inhalant deposition at the obstruction site, and alterations
in tissue expansion due to disease that cause preferential airﬂow to
healthy regions of the lung [25] and hence more inhalant deposition
in these regions [27]. Therefore, the underlying functional deﬁcit due
to disease, the site of deposition, and the functional recovery due to
treatment form a feedback loop that dramatically inﬂuences theInhaled treatment 
distribution
Fluid mechanics
Bacterial
infection
Pathophysiology
Regional 
lung function
Response to 
treatment
Fig. 2. Feedback in inhaled treatment of respiratory infections. Regional lung function,
inhaled treatment distribution and bacterial infection form a feedback loop, whereby
lung function, which is altered due to the underlying pathology, determines the inhaled
treatment distribution, which strongly inﬂuences the treatment effectiveness and hence
pathological response.effectiveness of treatment (Fig. 2). Measurement of local lung function
would provide new insight into these interactions, improving our un-
derstanding of the physiological consequences of lung infection, but
also the factors that inﬂuence effective inhaled delivery of treatments.
Imaging is underutilized in pharmaceutical drug development, with
imaging performed on only about 1% or 2% of animals used in the
preclinical stages of drug development [28]. Development of truly func-
tional imagingmethods would harness the power of regional measure-
ments and provide added sensitivity and information for assessment of
novel treatments.1.3. Use of imaging for investigation into inhaled treatment deposition
The distribution of deposition within the lung of an inhaled treat-
ment agent clearly has a large inﬂuence on the effectiveness of that
treatment. It is important, therefore, to separate the effect of the deliv-
ery mechanism from the pharmacological action to accurately assess
its suitability. An otherwise viable treatment may be ineffective if the
antibiotic is not delivered in sufﬁcient concentration to the infected
areas within the lung. This may cause direct detriment to the patient,
and may also lead to a potentially viable pharmaceutical treatment
being rejected during development due to apparent ineffectiveness.
During inspiration, gas ﬂow reduces in the lung through each
successive bifurcation generation, as the ﬂow is divided between more
and more airway branches. Turbulence, separated ﬂow, and recircula-
tion may occur in the proximal airways, particularly around airway
bifurcations. Larger and denser particles preferentially deposit on the
inner wall downstream of the ﬁrst few bifurcations, as their greater
inertia causes them to impact the airway wall in these regions. As the
ﬂow rate reduces through each generational branching, the ﬂow
becomes increasingly laminar, and diffusion becomes the predominant
gas mixing mechanism in the distal airways. Deposition mechanisms
that predominate in smaller airways are gravitational sedimentation,Fig. 3. Various inhalant deposition mechanisms. In high ﬂow regions, inertia causes larger
particles to impact the airway wall, whereas smaller particles tend to deposit in distal
airways due to diffusion, sedimentation or electrostatic forces.
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er particles traverse the lung without depositing to be expelled upon
exhalation. In this way, the ﬂuid mechanics and particle properties
interact to determine the site of deposition.
A signiﬁcant challenge in determining the interaction between local
function and inhaled deposition lies in the fact that regional airﬂow, the
major factor in deposition distribution, is difﬁcult to measure in vivo.
Although recent advances in functional imaging are addressing this
challenge, widespread use of these methods has not yet been achieved.
An additional challenge is that directly measuring inhalant deposition
non-invasively at high resolution is difﬁcult to achieve. Themost widely
used imaging method for determination of regional particle deposition
has been nuclear imaging. In this method, a radionuclide contrast
agent is inhaled into the lung, and the emitted high energy radiation is
imaged using gammadetectors to provide local concentrationmeasure-
ment of the inhaled agent [29]. This can provide regional measurement
of deposition. However, spatial resolution is not sufﬁcient to localize
deposition measurement to speciﬁc airway locations. These two
challenges mean that directly correlating airﬂow with inhaled treat-
ment deposition experimentally has been thus far unachievable.
The lack of acceptable experimental data has necessitated a focus on
computer simulation to investigate the various factors that contribute to
particle deposition. Although effective for fundamental studies of depo-
sition, for computer simulation to accurately predict inhaled treatment
deposition, detailed knowledge of airway geometry and pressure/ﬂow
inputs in both health and disease are required. As these data are not
readily available, investigators must often resort to assumptions that
can drastically inﬂuence results, reducing the ability of simulations to
accurately reﬂect the real-world situation [30–32].
A common assumption is that the airway tree is rigid and static.
Often the geometry of the airway tree is measured from computed
tomography (CT) images acquired during a breath-hold maneuver
[33–38]. Mead-Hunter et al. (2013) [30] studied the effect of the static
airway geometry simpliﬁcation on deposition distributions calculated
from numerical modeling. Signiﬁcant differences in the predicted depo-
sition patterns were found between the simulations using a dynamic
(moving) airway geometry compared with those simulated using a
static airway tree. This highlights the sensitivity of inhalant deposition
to dynamic effects, and demonstrates the importance of including
dynamics in deposition modeling.
As an additional input into computer simulations of particle deposi-
tion, several studies have used changes in lobar volume measured from
CT images at two phases of the breathing cycle, to estimate the ﬂow into
peripheral airways [33,36,37]. Steady ﬂow is often imposed between
these two phases, which are typically chosen to be functional residual
capacity and total lung capacity. Although an improvement over spatially
uniform pressure/ﬂow simpliﬁcations, this method does not take into
account dynamic effects throughout the respiratory cycle that may affect
inhaled treatment distribution, and also neglects intra-lobar variability.
The emerging dynamic imaging methods described in this review
can provide invaluable information for modeling studies. This will obvi-
ate many of the assumptions and simpliﬁcations currently employed,
resulting in much improved deposition distribution simulations for
study and optimization of inhaled treatments.2. Established lung imaging methods
There are several imaging methods that are well developed for the
lung. Although these provide very useful information, there are several
capability limitations that hinder use in particular situations. In this
section we provide an overview, explain the technical principles, and
describe the advantages and disadvantages of each technology. Our
goal is to provide a working knowledge of the capabilities of each
imagingmode, allowing assessment of their potential for use in investi-
gations into pulmonary infection and inhaled treatments.2.1. Computed tomography
The current gold standard for lung imaging is computed tomography
(CT), which is capable of providing high-resolution three-dimensional
images of the internal structures of the lung. To achieve this, X-ray
images are acquired from multiple viewing angles. These projections
represent line integrals of the X-ray transmission of the sample from
different angular orientations. The three-dimensional lung structure is
reconstructed from these projections using back-projection or iterative
methods [39]. The spatial resolution of the projections and the number
of viewing angles used in the reconstruction determines the resulting
spatial resolution of the reconstruction. Therefore, a high-resolution CT
scan requires many high-resolution projection images to be acquired.
CT scanners predominantly employ a single source and detector pair
that is rotated around the subject to collect the required projection data.
Movement of the subject during a scan results in artifacts in the recon-
struction that degrade image quality and spatial resolution. Therefore,
CT is best performed on stationary objects. To reduce these artifacts in
the case of lung imaging, CT scans of the lungs are typically acquired
during a breath-hold maneuver.
As with all X-ray based imaging methods radiation dose is a signiﬁ-
cant concern when using computed tomography in vivo. The ionizing
nature of absorbed X-rays can damage DNA, either directly, or through
the creation of free-radicals. For this reason, X-ray dose signiﬁcantly
increases the probability of developing cancerous tumors. It is therefore
necessary to minimize radiation dose in X-ray imaging methods. This
factor is most critical in CT, where the use of many X-ray projection
images results in high radiation exposure [40]. The requirement for
minimization of dose means that it is difﬁcult to perform repeated
imaging at high resolution to investigate the progression of infection,
or to monitor the effectiveness of inhaled treatments over time.
Xenon gas may be used as a contrast agent and combined with
washout techniques to determine regional ventilation [41,42]. Howev-
er, this requires serial CT imaging, signiﬁcantly increasing X-ray dose.
Additionally, as the density and viscosity of Xenon gas is much greater
than air, the distribution of Xenon gas may not accurately reﬂect the
regional ventilation of respiratory gases under normal conditions [42].
Nevertheless, CT has the ability to provide measurement of lung
health in a variety of conditions. For example, Galbán et al. [43] used
changes between two CT reconstructions (one at end inspiration, and
one at end expiration) as a surrogate biomarker for chronic obstructive
pulmonary disease. Using this method they were able to assess the
regional severity of the disease. De Langhe et al. [44] quantiﬁed lung
ﬁbrosis and emphysema inmice using computed tomography.Wielputz
et al. [45] utilized a low-dose computed tomographymethod tomonitor
cystic ﬁbrosis lung disease in mice over time. Kobayashi et al. [46]
utilized micro-computed tomography to assess emphysema in a COPD
exacerbation mouse model.
CT can be utilized to provide either an indirect assessment of lung
health through biomarkers, or a direct measurement of lung health
where structural changes in lung tissue can be resolved. Unfortunately,
many lung diseasesmay produce signiﬁcant functional changes for only
subtle changes in lung structure that may not be readily deduced from
static CT imaging.
2.2. Ventilation measurement using 4DCT registration-based methods
The motion of lung tissue is integrally connected to its function. The
ﬂow of air into a region of the lung results from the expansion of that
tissue, and hence measurement of lung tissue expansion over the
breathing cycle allows inference of regional airﬂows throughout the
lung.
CT has been combinedwith image registration techniques to provide
measurement of lungmotion. Image registration is an image processing
method that allows matching of the spatial location of a landmark or
object between two separately acquired images. Several studies have
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two volumetric lung images acquired using CT in two breath-hold states
[47–50]. Unfortunately, data acquired in this way does not truly capture
the dynamics of breathing.
An alternative approach that provides dynamic imaging exploits the
periodic motion of the lung during the breathing cycle. Respiratory
gating is used to sort projection data into speciﬁc phases of the breath,
allowing phase-averaged 4DCT of the lung to be performed at various
points in the breathing cycle. Several studies have combined 4DCT
with image registration to measure lung motion and regional ventila-
tion during thebreathing cycle [51–53]. These data can beused to assess
the health of the lung tissue. For example, Yamamoto et al. [54] demon-
strated this technique for measurement of regional disease in patients
with emphysema.
Themajor limitation for this approach is a requirement to expose the
subject to high radiation dose. 4DCT-based measurement of ventilation
requires at least one additional CT scan to be acquired for each time-
point measured, multiplying the dose required dramatically. The high
radiation dose makes serial imaging impractical and limits the use of
4DCT to subjects where the signiﬁcant risks of large radiation dose are
acceptable: for example, patients with advanced disease or preclinical
models.
2.3. Hyperpolarized magnetic resonance imaging
Magnetic resonance imaging (MRI) utilizes the radiofrequency
signals emitted by polar nuclei when their spin is modiﬁed by an exter-
nally appliedmagnetic ﬁeld in order to generate 3D images of biological
subjects. Hydrogen atoms contain polar nuclei and are found in abun-
dance in soft tissue, providing an ideal material for imaging with MRI.
However, the inﬂated lung is approximately 80% air, and the resulting
low tissue density within the lung results in poor image quality.
To overcome this problem, hyperpolarized noble gases have been
produced that enhance the MRI signal by several orders of magnitude
when inhaled. Regional variation in ventilation distribution can be
obtained, because the signal is proportional to the concentration of
gas within the lung regions [55]. Additionally, by utilizing specialized
magnetizing sequences, other functional measurements may be per-
formed such as lung microstructure, oxygenation and perfusion [56],
although with varying degrees of success.
MRI imparts no radiation dose, a major advantage over X-ray based
imaging methods. However, despite recent improvements, the resolu-
tion is still signiﬁcantly lower than CT.
Despite recent advances, there exist a number of challenges hinder-
ing widespread use of hyperpolarized MRI [56]. Cost is the most signif-
icant factor. The production of hyperpolarized gases is expensive, and
the limited half-life of these gases causes signiﬁcant logistical issues.
Additionally, highly specialized and expensive technology is required
to produce the necessarily strong magnetic ﬁelds used for imaging
the hyperpolarized gases [57]. Perhaps due to the prohibitive cost of
hyperpolarized MRI, no substantial study has yet demonstrated the
relative sensitivity and speciﬁcity advantages of this method over
other modalities.
2.4. Electrical impedance tomography
The electrical impedance of regions within the chest will vary de-
pending on the proportion of the various constituents. The proportions
of blood, tissue, and air in the chest cavity will vary both spatially and
over the respiratory and cardiac cycles. Electrical impedance tomogra-
phy (EIT) uses the varying impedance in the chest to measure changes
in ventilation and perfusion during breathing [58–60].
In EIT, electrodes are placed around the chest, and voltage proﬁles
are collected for all drive and receive electrode–pair combinations.
Tomographicmethods are used to reconstruct the time varying electrical
properties within the lungs during breathing, allowing the proportionof blood, tissue and air inside the chest to be mapped, and regional
ventilation and perfusion to be calculated. Electrical impedance tomog-
raphy has many advantages for clinical application. The simple and
compact hardware required are well suited to measurement at the bed-
side. However, EIT is fundamentally limited by maximum number of
electrode/detector pairs that can be practically used, resulting in an ill-
posed reconstruction problem and spatial resolutions far lower than CT
or MRI based modalities [58].
EIT is a useful clinical tool for monitoring the lung function of pa-
tients. However, for investigation into respiratory infection and inhaled
treatments where smaller scale functional changes are important, the
lack of spatial resolution limits the utility of EIT.
2.5. Nuclear medical imaging
Nuclear medical imaging methods utilize the detection of gamma-
ray photons emitted by radioactive contrast agents within a subject.
The radiolabeled substance is used to preferentially target an organ or
disease process. There are three major imaging modes that are catego-
rized as nuclear medical imaging: gamma scintigraphy, positron
emission tomography (PET), and single photon emission computed
tomography (SPECT).
Although localization of the labeled pharmaceutical compound to
speciﬁc areas can provide excellent contrast, nuclear medicine tech-
niques generally suffer from poor signal-to-noise as the amount of
radioactive material must be minimized for the safety of the subject.
Although spatial resolutions have improved dramatically over the past
decade, temporal resolution remains poor [61].
Nuclear medicine enables studies of lung function to be carried out,
including the determination of regional ventilation and gas exchange
[13, 63–64]. For functional lung imaging, this radioactive agent is in-
haled into the lungs. Functional lung measurements using nuclear im-
aging are well suited for testing of efﬁcacy of inhaled treatments to
provide a measure of a treatment success from a functional, as opposed
to anatomical, perspective. Additionally, the functional data obtained
may be used as a validation for numerical simulation [33].
Radionuclide agents can be tagged to speciﬁc materials, and conse-
quently nuclear imaging can be used to directly track deposition of
pharmaceutical compounds into the lung – a highly useful tool for in-
haled treatment development [29]. Gamma scintigraphy can be used
to measure the distribution of aerosols within the lung [65–68]. The
lack of spatial resolution of gamma scintigraphy has generally limited
the measurement of the distribution of aerosol deposition to statistical
metrics, such as the penetration index (the ratio of peripheral to central
deposition), the coefﬁcient of variation, the coefﬁcient of skewness and
the quotient between maximum and mean value deposition [66]. For
example, Laube et al. (2000) [69] used gamma scintigraphy to measure
the penetration index of radio-aerosol in CF patients. The study demon-
strated that the penetration index could be manipulated by changing
the patient's inspiratory ﬂow rate, but the precise site of deposition
with respect to any pathologies present was not determined. PET
imaging provides the best regionality and resolution for measurement
of deposition distributions [29,70,71]. However, practical challenges
limit its widespread use, such as difﬁculties in producing radiolabeled
drug analogues and the very short half-lives of suitable radionuclides [72].
3. Emerging functional imaging
In the previous section, we describe several imaging technologies
that have been used extensively for lung imaging. However, there is a
need for further advances to address the key shortfalls of the current
technology for providing sufﬁcient functional lung imaging capability
to address regional lung disease and inhaled treatments. The key will
be to deliver sufﬁcient resolution and contrast in the lung, while
maintaining a dynamic imaging capability. Over the last decade,
synchrotron-based phase-contrast imaging methods have made huge
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ation are advantageous for imaging within the lung, and translation of
these techniques to laboratory-based X-ray sources, and eventually to
clinical application promises to provide lung imaging modalities with
unprecedented capabilities.
In this section we describe synchrotron-based phase contrast imag-
ing and give examples of its use in the lung. Recent efforts in translation
of these technologies to laboratory-based systems are then detailed.
3.1. Phase-contrast imaging
X-ray imaging traditionally utilizes absorption contrast, whereby
materials with differing X-ray attenuation properties are differentiated
by the intensity of the X-rays that transmit through them onto an
X-ray detector. Structures consisting of heavily attenuating materials
will appear darker than those containing less attenuating materials.
Bone is highly attenuating, and therefore provides high contrast against
the surrounding soft tissue. Conversely, the lung parenchyma and
surrounding tissue have similar bulk attenuation properties, and thus
the lungs generate poor contrast.
Phase-contrast imaging utilizes the difference in refractive proper-
ties of materials to generate contrast. Differential changes in the phase
of a partially coherent X-ray wave, imparted by different materials in
the sample, can be made visible as a consequence of interference with
an unperturbed wave. Phase gradients are largest at the boundaries
between materials, and hence phase contrast has a predominantly
edge enhancing effect.
X-ray sourceswith high spatial and temporal coherence are required
for phase contrast imaging. Synchrotron radiation sources are extreme-
ly bright, which enables conditioning of the X-ray beam to create very
high coherence while maintaining sufﬁcient ﬂux to image with good
temporal resolution. The X-ray energy can be ﬁltered to produce a
monochromatic beam to improve temporal coherence, while the
distance from the X-ray source to the sample can be increased to reduce
the effective spot size and increase spatial coherence [61]. Notwith-
standing these advantages, synchrotron radiation sources are highly
expensive, and consequently access to these X-ray sources is limited.
Therefore, to become widely utilized, the phase contrast imaging
technologies developed on the synchrotron must be translated into
the laboratory setting, and ultimately to clinical application. Recent
developments towards this initial translation to laboratory sized X-ray
sources have generated promising results, and widespread laboratory
based phase-contrast imaging is now within reach [73–77].
Phase contrast imaging is ideally suited for imaging of the lung, as
the many air–tissue interfaces in the lung provide very large X-ray
phase gradients. Therefore, phase contrast can provide signiﬁcant
improvements in contrast anddetail over absorptionbasedX-ray imaging
[61,78–80].
Several methods for generating phase contrast have been applied to
the lung, with the two most predominant being grating interferometry
and propagation-based imaging (PBI).
3.2. Grating interferometry
Grating interferometry [81,82] uses phase-gratings placed between
the sample and detector to generate contrast from the phase changes
imparted on the X-raywave by the sample. These grating are placed be-
tween the detector and the sample, effectively resulting in a reduction
in efﬁciency of the system to detect X-rays. To overcome this, very
brightX-ray sources, or increased exposure times are required, resulting
in a relative increase in X-ray dose imparted to the sample.
Grating interferometry performswell with X-ray sources that exhib-
it lower coherence, making these methods well-suited for translation
from the synchrotron to the lab. Consequently, recent studies have
used grating interferometry on a laboratory-based X-ray source [83]
with several of these studies relating to lung imaging [84–86].Schwab et al. [86] demonstrated improved contrast in excised
healthy mouse lungs using grating-based imaging on a compact
laboratory-based synchrotron. This same imaging setup was also used
by Schleede et al. [85] to demonstrate improveddiagnosis of emphysema,
by comparing the ratio of the phase signal to the attenuation signal, a
surrogate marker for alveolar size.
Meinel et al. [84] attempted to use a similar measure on the same
setup for improvement of lung cancer detection. Although the prelimi-
nary results did not show an increase in sensitivity, delineation of the
cancer boundary was improved through the edge enhancing effect.
Grating interferometry shows potential for use in assessing lung
function and the effectiveness of inhaled treatments. Although this ap-
proach is potentially very sensitive in some cases, the data obtained
are structural and thus can only provide anatomical markers for lung
health rather than produce functional markers. Furthermore, until
temporal resolution is improved dynamic measurements over a breath
will not be possible, further limiting utility.
3.3. Propagation-based phase-contrast imaging
The simplest method for generating phase-contrast is propagation-
based phase contrast imaging (PBI), sometimes called in-line X-ray
phase contrast imaging. By allowing the X-ray wave to propagate a
large distance between the sample and detector, interference fringes
are generated at the detector plane by the X-ray waves that are slightly
refracted at the surface interfaces contained in the sample. The ability to
image in phase contrast without gratings or other apparatus between
the sample and detector provides a higher efﬁciency, and therefore
increased capability for dynamic imaging [78,87–90]. There have been
a number of studies that utilize planar PBI for in vivo lung imaging,
taking advantage of a simple implementation and capacity for dynamic
imaging. For example, Hooper et al. [91] visualized liquid clearance in
live newborn rabbit pups as they take their ﬁrst breaths. Kitchen et al.
[92] described a method for calculating ventilation from dynamic
imaging of lungs using PBI, demonstrating the possibility for functional
metrics to be derived from phase contrast images.
The use of dynamic PBI for investigations into inhaled drug delivery
has been demonstrated in several recent studies, and development of
image processing and experimental methods stemming from this tech-
nology has accelerated in recent years. These studies have exploited the
dynamic capabilities of synchrotron PBI in order to probe both the effec-
tiveness of treatments and the efﬁcacy of the delivery methods.
Donnelley et al. [93] used high-resolution synchrotron PBI for the detec-
tion of inhalable particles in livemouse airways. Subsequent to this, pol-
lutant and other marker particles were used to measure mucociliary
transport mechanisms [94]. PBI has been used to measure airway
surface liquid depth, speciﬁcally for assessment of therapies for cystic
ﬁbrosis lung disease [95,96]. Donnelley et al. [97]measured the variabil-
ity of in vivo ﬂuid dose distribution in liquid doses delivered through
the pulmonary system. The affect of airway hydrating therapies on
mucociliary transport [98,99] has also recently been investigated using
synchrotron phase contrast imaging.
3.4. Functional lung imaging using phase contrast
The increased spatial detail and temporal resolution resulting from
PBI provides the opportunity to extract quantitative functional informa-
tion on the lung using advanced image processing methods.
Motion tracking methods, originally developed to measure ﬂuid
ﬂow in engineering applications, have been adapted to measure the
movement of lung tissue in dynamic PBI images [11]. Expansion of
lung tissue is directly linked to air ﬂow into, or out of, regions of the
lung, and measurement of the lung expansion can be used to calculate
airﬂow distributions throughout the lung [100], thus adding a function-
al measurement capability to dynamic X-ray imaging.
Fig. 5. Computed tomographic X-ray velocimetry reconstruction of lung motion. Vectors
show speed and direction of lung tissue of a mouse during inspiration. Motion
ﬁeld was reconstructed using computed tomographic X-ray velocimetry from 6 images
(3 simultaneously captured views at two-time points) acquired using liquid-metal jet
X-ray sources. Skeletal information is acquired from a co-registered high-resolution CT.
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dramatically in the presence of lung injury, providing improved
sensitivity and earlier detection of disease over other methods.
Dubsky et al. [100] developed a method for 4D dynamic measure-
ments of airﬂow throughout the entire lung (Fig. 4). This method can
provide both regional functional information for disease detection or
assessment of treatments, and also high quality functional inputs for
computational modeling. This method has been shown to improve
accuracy and sensitivity for detection of cystic ﬁbrosis lung disease
over spirometric methods [26]. This method is based on 4DCT, and
therefore imparts signiﬁcant dose to the subject. However, our research
group has also developed a novel method that can reduce the dose by
orders of magnitudes, allowing 4D measurement of lung motion from
as few as 6 images [101–103] (Fig. 5). By producing functional images
without the requirement for phase gating, as in 4DCT, this method can
measure short-lived effects, signiﬁcantly broadening the scope of
treatments and conditions that can be assessed, particularly for investi-
gations into inhaled treatments for which the functional effects are
often transient.
Functional lung imaging using phase-contrast has been demonstrat-
ed to outperform current imaging methods for the assessment of
disease and treatments. However, the requirement for synchrotron
radiation severely limits its widespread adoption. In order to fully
realize the potential in this ﬁeld, translation from the synchrotron to
the laboratory, and then into the clinic, is critical.
3.5. Laboratory propagation-based phase-contrast imaging
Almost 20 years ago, it was demonstrated that PBI could be per-
formed on a laboratory source with sufﬁcient spatial coherence [104].
However, only recent developments in X-ray source technology have
enabled this method to achieve sufﬁcient temporal resolution to be
useful for lung imaging. The challenge lies in creating an X-ray source
that provides adequate power while maintaining a source spot size
small enough to deliver the required spatial coherence.
Garson et al. [105] demonstrated that lung images of similar quality
to those acquired at a synchrotron can be produced using laboratory-
based sources. However, the relatively low power of the X-ray source
used resulted in exposure times that are too long for dynamic or
in vivo studies.t = 0.000
t = 1.000
Fig. 4. Distribution of ﬂow throughout the airway tree, measured using functional lung imagi
sequence of 20 timepoints) during ventilation. Positive ﬂow (red) indicates inspiratory ﬂow anRecently, the development of liquid-metal-jet X-ray sources opens
up the possibility for dynamic PBI in the laboratory. These X-ray sources
provide unparalleled brightness for small spot sizes, allowing for very
high quality phase contrast imaging with reduced exposure times
[75]. Use of the liquid-metal-jet source for PBI has been demonstrated
in a number of applications, including for high-resolution angiography
[76] and cancer demarcation in small animals [77].
It has recently been demonstrated that successful high-resolution
dynamic phase-contrast in vivo lung imaging can be effected using a
liquid-metal-jet laboratory X-ray source (Excillum, D2) [74]. Usingt = 0.058 t = 0.116
t = 1.058 t = 1.116
0.5 
0.0
-0.5
m
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ng. Instantaneous ﬂow of air through the rabbit pup airway tree at six time points (from
d negative ﬂow (blue) indicates expiratory ﬂow [100].
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imaging from the synchrotron the laboratory is within reach, and the
full potential of these methods will be realized in the near future.
4. Conclusions
Respiratory infection has signiﬁcant regional effects on lung func-
tion. Additionally, the efﬁcacy of treatment delivered through inhalation
is strongly inﬂuenced by regional lung function. This feedback loop
must be understood in detail for accurate assessment of new and devel-
oping treatments and delivery systems. This requires advancement of
functional lung imaging beyond the currently available methods to
improve both spatial and temporal resolution.
We have identiﬁed three critical unmet needs for functional lung
imaging in the ﬁeld of respiratory infection: (1) regional assessment of
functional consequences of pathology, and (2) regional assessment of
response to inhaled treatment, and (3) input into deposition modeling
studies.
No established imagingmodalities can provide high-resolution func-
tional measurements to adequately address these needs. Emerging
methods based on synchrotron phase contrast imaging have the poten-
tial to fulﬁll these requirements, and a recent trend of translation to
laboratory applications and into the clinical setting offers enticing possi-
bilities beyond research into treatments and inhaled delivery methods.
There also exists the potential for functional lung imaging to become
core to the treatment process. The capacity to provide accurate regional
assessment of disease, and patient speciﬁc deposition modeling, opens
the possibility of sophisticated tailoring of inhaled treatment parame-
ters (size of particles, concentration, inspiratory ﬂow rate) in order to
target the most diseased areas. Additionally, these parameters can be
effectively adapted over the course of the treatment as the patient's
function changes and improves. This full integration of imaging and
modeling as a companion diagnostic to antibiotic treatment has the
potential to dramatically improve efﬁciency and effectiveness of inhaled
treatments, leading to substantially improved patient outcomes.
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